UPMC Physician Resources

Archives for UPMC

American Thoracic Society 2017 Respiratory Heath Awardees — Steven Shapiro, MD, and Alison Morris, MD

SHAPIRO_STEVE_MD_EVP_20140204_004Steven Shapiro, MD and Alison Morris, MD have been named 2017 Respiratory Health Awardees by the American Thoracic Society (ATS). The Respiratory Health Awards will be presented at several events during the ATS conference. The 2017 American Thoracic Society Conference (ATS) will be held May 19-24 in Washington, DC.

Dr. Shapiro is receiving the Distinguished Achievement Award. The Distinguished Achievement Award is given to individuals who have made outstanding contributions to fighting respiratory disease through research, education, patient care, or advocacy.

Dr. Shapiro leads the Health Services Division as an executive vice president of UPMC, along with his overarching responsibility as chief medical and scientific officer for this integrated delivery and finance system.

In collaboration with the University of Pittsburgh Schools of the Health Sciences and the UPMC Insurance Services Division, Dr. Shapiro is promoting evidence-based care pathways and population health models that position UPMC to provide the highest value and quality to patients.

MORRIS_ALISON_MD_PUL_AI_CC_20130131Dr. Morris is receiving the Recognition Award for Scientific Accomplishments. The Recognition Award for Scientific Accomplishments recognizes outstanding scientific contributions in basic or clinical research to enhance the understanding, prevention and treatment of respiratory disease or critical illness. Awardees are selected based on contributions made throughout their careers or for major contributions made at a particular point in their careers. Awardees will make a 25-minute presentation on their research.

Dr. Morris’ research interests include HIV-associated lung disease as well as the role of the microbiome in disease. Her group works with large cohort epidemiologic studies of HIV and other diseases as well as in translational studies in which physiologic and molecular techniques are applied to patient populations.

As part of her role in the Center for Medicine and the Microbiome, she works with collaborators in diverse areas studying the microbiome. Her clinical interests focus on lung disease in HIV-infected patients and in care of intensive care unit patients.

Children’s Hospital of Pittsburgh of UPMC Pulmonary Chief Elected Secretary-Treasurer of the American Thoracic Society

CELEDON_JUAN_MD_PDP_20131105_CSThe American Thoracic Society (ATS) has elected Juan C. Celedón, MD, DrPH, chief, Division of Pulmonary Medicine, Allergy and Immunology at Children’s Hospital of Pittsburgh of UPMC, as its Secretary–Treasurer for the 2017–18 term.
Dr. Celedón will then assume the role of ATS President for the 2020 21 term and notably will be the first ATS president from the University of Pittsburgh, as well as the first Latino American to serve as ATS president, in the 115-year history of the society.

“I am deeply humbled and honored to have been elected as the Secretary-Treasurer of the American Thoracic Society, arguably the leading professional society in academic pulmonary, critical care and sleep medicine worldwide,” said Dr. Celedón, Niels K. Jerne Professor of Pediatrics, University of Pittsburgh School of Medicine. “I hope to further the mission of the ATS in achieving respiratory health equality and workforce diversity, while continuing to pursue excellence in research, education and training, as well as clinical care of patients with pulmonary diseases, critical illnesses and sleep disorders.”

“On behalf of the ATS community, we wholeheartedly welcome Dr. Celedón to the elected leadership of the Society,” said David Gozal, MD, MBA, president of the ATS. “His previous achievements and recognition have clearly earned him this honor. We look forward to his future contributions to the ATS and to the field of pulmonary, critical care and sleep medicine both nationally and around the world.”

Dr. Celedón has been a member of the ATS since 1993. He received from the ATS the “Recognition Award for Scientific Accomplishments” in 2014, and was the first-ever recipient of the “Lifetime Award for Innovations in Health Equality” in 2015.

His research has focused on asthma and COPD, and on health disparities in airway diseases. His research, which has been funded by the National Institutes of Health, has been recognized with his election to the American Society for Clinical Investigation and the Association of American Physicians.

Dr. Celedón, who also serves as professor of Medicine, Epidemiology and Human Genetics at the University of Pittsburgh, will be installed as Secretary–Treasurer in May at the ATS 2017 International Conference in Washington, DC.

Founded in 1905, the American Thoracic Society is the world’s leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.

For more information on Dr. Celedón, visit www.chp.edu.

2017 Update in Abdominal Transplantation Medicine and Surgery — May 12

UPMC Transplant Services, the UPMC Liver Cancer Center, and the UPMC Center for Liver Diseases will host the 2017 Update in Abdominal Transplantation Medicine and Surgery on Friday, May 12. The conference will be divided into two courses – a liver course and a kidney course and will provide health care professions an overview of current trends, management techniques, and new innovations and research to treat liver and kidney diseases.

Friday, May 12

Registration will begin at 7:30 a.m.

Fairmont Pittsburgh
510 Market St.
Pittsburgh, PA 15222

Liver Topics:

•    Living-Donor Liver Transplant
Presented by: Abhinav Humar, MD

•    The Nuts and Bolts of the Liver Transplant
Presented by: Christopher Hughes, MD

•    Predictors of Mortality on the Liver Transplant Waiting List and Early Intervention
Presented by: Swaytha Ganesh, MD

•    Non-Alcoholic Fatty Liver Disease: Non-invasive Evaluation and Treatment Options
Presented by: Jaideep Behari, MD, PhD

•    Intestinal Rehabilitation and Transplantation Solutions for Complex Gastrointestinal Problems
Presented by: Ruy Cruz, MD

 Kidney Topics:

•    Living-Donor Kidney Transplant
Presented by: Amit D. Tevar, MD

•    Antibodies: HLA Typing, CPRA, Crossmatching, and Antibody-Mediated Rejection
Presented by: Puneet Sood, MD, MPH

•    Kidney Transplantation for the Pediatric Patient
Presented by: Armando Ganoza,

•    Is My Patient a Candidate: Listing Elderly, Obese and Patients with Cancer
Presented by: Christine Wu, MD and Amit D. Tevar, MD

•    Long-term Medical Management of Renal Transplant Patient
Presented by: David J. Levenson, MD

Registration

For more information or to register, please visit UPMC.com/AbdominalTransplantConference2017.

The International Society for Heart and Lung Transplantation (ISHLT) 37th Annual Meeting and Scientific Sessions — April 4-8, San Diego

The UPMC Heart and Vascular Institute and UPMC Cardiothoracic Transplant Department will be well-represented at the International Society for Heart and Lung Transplantation (ISHLT) 37th Annual Meeting and Scientific Sessions in San Diego, Ca. Faculty research will be featured in both oral and poster presentations throughout the conference, including:

 

Tuesday, April 4

ACAD Core ID – ISHLT Academy: Core Competency Course in Infectious Diseases in Thoracic Transplantation and Mechanical Circulatory Support

SESSION 2: This Could Happen to You…Drug Interactions and Toxicity Errors to Avoid with Anti-infectives and Immunosuppression and Cracking the Therapeutic Drug Monitoring Code

Presented by: Christopher R. Ensor

 

Wednesday, April 5

Opening Plenary Session

Co-Chair: Jeffrey J. Teuteberg

 

Symposium: When Should We Call It Quits? The Efficacy of Interventions to Ameliorate Psychosocial Risk Factors

When Do We Call It Quits: Intervention Strategies and Outcomes for Medical Non-Adherence

Presented by: Mary Amanda Dew

 

Are All Substances Made Equal?

Presented by: Andrea DiMartini

 

Oral Session: Cutting Edge Updates in Infectious Diseases

0039 – Clinical Risk Factors for Invasive Aspergillosis in Lung Transplant Recipients: Results of an International Cohort Study

Presented by: C. Aguilar, B. Hamandi, C. Fegbeutel, F. P. Silveira, E. A. Verschuuren, P. Ussetti, P. V. Chin-Hong, A. Sole, C. Holmes-Liew, E. M. Billaud, P. A. Grossi, O. Manuel, D. J. Levine, R. G. Barbers, D. Hadjiliadis, L. Singer, S. Husain

 

Oral Session: Bugs and Devices: A Bad Combination

0047 – Epidemiology of Fungal Infections (FI) in Mechanical Circulatory Support Device (MCSD) Recipients: Analysis of IMACS Registry 2013-2015

Presented by: O. Morrissey, R. Xie, J. Schaenman, S. Husain, M. Mooney, T. Nakatani, R. Kormos, M. Gómez-Bueno, S. Aslam, Y. Pya, M. Hannan

 

Symposium: Thinking Outside the Box: Extra-Pulmonary Management in Lung Transplantation

New Lungs – Old Sinuses: Friends or Foes?

Presented by: Joseph M. Pilewski

 

Mini Oral Session: Allocation, Bridging and Lung Allograft Assessment Strategies

0116 – Mechanical Ventilation and Extracorporeal Membrane Oxygenation (ECMO) as a Combined Bridging Strategy to Lung Transplantation: Significant Gains in Survival

Presented by: A. L. Du, J. Hayanga, J. D’Cunha, M. Tuft, M. Morrell, N. Shigemura

 

Mini Oral Session: The Hardware of MCS

0131 – Association Between the Use of Invasive Hemodynamic Monitoring and Outcomes with Percutaneous Left Ventricular Support: A Call for Standardization?

Presented by: J. J. Teuteberg, W. O’Neill

 

0132 – Analysis of Right Ventricular (RV) Regional and Global Systolic Function by Gated Blood Pool SPECT (GBPS) in Patients Undergoing Left Ventricular Assist Device (LVAD) Implantation

Presented by: C. B. Link, A. Nayak, P. Soman, M. A. Simon, J. J. Teuteberg, L. Lagazzi, A. Althouse, R. Kormos.

 

Poster Session 1: Heart Failure

0563 – Does Heart Failure with a Lower Ejection Fraction Mean Higher Costs? Insights from Data Analytics Across a Large Health Care System

Presented by: C. B. Link, S. Koscumb, P. Lynch, R. Ramani, M. Shullo, O. Marroquin, J. J. Teuteberg

 

0570 – Utilizing Data Analytics to Identify Patients at Highest Risk of Heart Failure Readmission

Presented by: C. B. Link, S. Koscumb, P. Lynch, R. Ramani, M. A. Shullo, O. Marroquin, J. J. Teuteberg

 

Poster Session 1: Junior Faculty Clinical Case Reports

0832 – Complications Following Lung Transplantation in a Patient with Short Telomere Syndrome

Presented by: C. Naik, M. Morrell

 

0847 – Successful Resolution of Refractory Rejection with Cyclophosphamide in a Lung Transplant Recipient Intolerant to Cell Cycle and Proliferation Signal Inhibitors

Presented by: C. A. Moore, M. R. Pipeling, C. R. Ensor

 

0865 – Pay Me Now or Pay Me Later: A Tale of Two Sensitized Pediatric Heart Transplant Candidates

Presented by: M. Mangiola, B. Feingold, D. Magnetta, S. West, S. Miller, M. Zinn, M. Marrari, A. Zeevi

 

Thursday, April 6

Sunrise Symposium: “Those Darn CARVs”: Community Acquired Respiratory Viruses in Lung Transplant

In the Pipeline: Novel Therapeutics

Presented by: Christopher Ensor

 

Symposium: Antibodies in Mechanical Circulatory Support: The Phantom Menace

Epidemiology and Risk of the Sensitized MCS Patient

Presented by: Michael Shullo

 

Symposium: Taming of the Shrew: Mycobacterium Abscessus in Lung Transplantation

Management of M. Abscessus in the Lung Transplant Candidate: Preparation for Transplantation

Presented by: Fernanda Silveira

 

Symposium: HLA, AMR and DSA – Approaching Antibodies in Kids

Before Transplant: Why the PRA Doesn’t Matter Anymore

Presented by: Brian Feingold

 

0225 – Neopterin Elevation and Survival Following Left Ventricular Assist Device Implantation

Presented by: M. M. Lander, M. Mercurio, K. Hanley-Yanez, M. S. Sharbaugh, A. D. Althouse, M. A. Simon, J. J. Teuteberg, L. Lagazzi, C. M. Sciortino, C. McTiernan, R. Kormos, D. M. McNamara

 

Oral Session: Contemporary LVAD Trials – Same Old Song or New Tune?

0150 – ENDURANCE Destination Therapy Trial Outcomes as Stratified by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Classification

Presented by: S. V. Pamboukian, F. D. Pagani, J. J. Teuteberg, R. L. Kormos, C. C. Caldeira, C. H. Selzmann, J. K. Kirklin, B. B. Reid, E. C. McGee, C. A. Milano, J. G. Rogers

 

Oral Session: Contemporary Challenges in Pediatric Heart Transplant

0182 – Impact of Newly Detected Donor Specific Anti-HLA Antibody in the First Year After Pediatric Heart Transplantation

Presented by: A. I. Dipchand, S. Webber, K. Much, B. Feingold, C. Bentlejewski, E. D. Blume, R. Shaddy, C. Canter, J. Lamour, W. Mahle, W. Zuckerman, H. Diop, Y. Morrison, B. Armstrong, D. Ikle, J. Odim, A. Zeevi

 

Mini Oral Session: Novel Strategies and Mechanisms in Lung Preservation, Heart Failure and Assist Devices

0215 – Microvasculature Analysis Using Micro CTA Techniques for Lungs After Different Preservation Process

Presented by: S. Tane, K. Noda, A. J. Hayanga, J. D’Cunha, J. D. Luketich, N. Shigemura

 

Poster Session 2: Lung Transplantation

Poster Discussant: Christopher R. Ensor

 

0988 – A Prophylaxis-Free, Pre-Emptive Approach to the Management of CMV After Lung Transplantation: Single Center Results

Presented by: A. Bertani, P. Vitulo, A. Mularoni, P. Grossi, L. De Monte, E. Russo, M. Beretta, L. Martino, A. Callari

 

Poster Session 2: Nursing, Health Sciences, Allied Health

Poster Discussant: Annette J. Devito Dabbs

 

Friday, April 7

Sunrise Symposium: Contrasts and Similarities in Children and Adults: IPAH, Portopulmonary Hypertension, and Perioperative Management

Co-Chair: Brian Feingold

 

Symposium: Dealing with Antibodies Before and After Heart Transplant

Co-chair: Michael Shullo

 

Symposium: E-Health, Wearables, Social Media and Big Data in Transplantation: Fancy Toys or True Care Innovations?

The Importance of Involving End-Users When Designing Interactive Health Technology Applications for Self-Management Support

Presented by: Annette Devito Dabbs

 

New Ethical and Legal Challenges Surrounding E-health in Transplantation

Presented by: JiYeon Choi, PhD, RN

 

Oral Session: New and Improving? Evolving Outcomes with MCS

0266 – Which INTERMACS 4-7 Patients Are at Low Risk for Mortality at One Year? Insights from the INTERMACS Database

Presented by: J. J. Teuteberg, A. D. Althouse, M. Shullo, N. Kunz, K. Lockard, E. Dunn, L. Lagazzi, C. Sciortino, J. Cowger, S. Joseph, R. L. Kormos

 

Oral Session: Saved by the Bell: Overcoming Adherence and Frailty

0331 – A Trajectory Analysis of Adherence to Recommended Exercise Following Lung Transplantation

Presented by: M. Alrawashdeh, J. Choi, A. DeVito Dabbs

 

Oral Session: PATH to Better Outcomes: Diagnostics in Heart and Lung Transplantation

0346 – Late Graft Dysfunction After Pediatric Heart Transplantation Is Associated with Fibrosis and Decreased Capillary Density by Automated, Whole-Slide Imaging

Presented by: B. Feingold, J. Picarsic, A. Lesniak, M. Wood-Trageser, B. Popp, A. J. Demetris

 

Oral Session: Heart Failure in MCS

0355 – The Duration of Inotropic Support and Survival After Left Ventricular Assist Device

Presented by: E. Grandin, D. Mooney, K. Kennedy, M. S. Kiernan, R. D. Kociol, J. J. Teuteberg, F. D. Pagani, A. C. Gaffey, P. Atluri, E. Y. Birati, S. Myers, D. Naftel, G. Oliveira, K. E. Simpson, R. W. Yeh, J. K. Kirklin, R. L. Kormos, J. Rame

 

0356 – The Incidence of Early and Late Clinical Right Heart Failure and the Impact on Survival After Continuous Flow Mechanical Support: Insights from the New INTERMACS Definition of Right Heart Failure

Presented by: J. J. Teuteberg, G. Studdard, F. Pagani, M. Kiernan, G. Oliveria, E. Rame, P. Alturi, A. Gaffey, E. W. Grandin, J. Kirlin, S. Myers, C. Collum, R. L. Kormos

 

Mini Oral Session: Pediatric Heart Failure, MCS, and Peri-Transplant Issues

0416 – Post-Transplant Outcomes of Patients Supported with the Berlin Heart EXCOR as a Bridge to Transplantation: A Multi-Institutional Study

Presented by: A. Jeewa, M. Imamura, C. Canter, R. Niebler, C. VanderPluym, D. Rosenthal, J. K. Kirklin, M. Tresler, M. McMullan, V. Morell, M. Turrentine, R. Amedur1, K. Nguyen, K. Kanter, J. Conway, R. Gajarski, C. D. Fraser Jr

 

Mini Oral Session: Assessing and Managing the Failing Right Ventricle

0434 – Painting Profiles of Ambulatory Advanced Heart Failure: A Report from the REVIVAL Registry

Presented by: M. M. Kittleson, P. Shah, A. Lala, R. McLean, S. Pamboukian, D. Horstmanshof, J. Thibodeau, K. Shah, D. Lanfear, J. Teuteberg, W. Taddei-Peters, S. Khalatbari, L. Stevenson, D. Mann, K. Aaronson, G. Stewart

 

Mini Oral Session: Patient Centered Outcomes in Advanced Heart and Lung Disease

0456 – Most Survivors Are Glad to Have a VAD

Presented by: L. W. Stevenson, J. Lindenfeld, K. Grady, J. Vader, M. Givertz, D. Naftel, T. Baldwin, S. Myers, R. Kormos, J. K. Kirklin

 

0457 – Slower Gait Speed as a Measure of Frailty Tracks with INTERMACS Profiles, Quality of Life and Predicted Mortality in Ambulatory Patients with Advanced Heart Failure: A Report from the REVIVAL Registry

Presented by: A. Lala, A. Ambardekar, J. Estep, J. Stehlik, M. Mountis, D. Haas, D. Horstmanshof, J. Thibodeau, K. Shah, D. Lanfear, J. Teuteberg, W. Taddei-Peters, S. Khalatbari, L. Stevenson, D. Mann, K. Aaronson, G. Stewart

 

Poster Session 3: Basic Science & Translational Research

1147 – Pyroptosis of Passenger Leukocytes Negatively Impacts the Quality of Lung Grafts During Ex Vivo Lung Perfusion

Presented by: K. Noda, S. Tane, A. J. Hayanga, J. D’Cunha, J. D. Luketich, N. Shigemura

 

1151 – Optimal Perfusate Oxygenation During Ex Vivo Lung Perfusion Can Promote Alveolar Proliferation in Lung Grafts

Presented by: K. Noda, S. Tane, A. J. Hayanga, J. D’Cunha, J. D. Luketich, N. Shigemura

 

1154 – DUAL Ex Vivo Lung Perfusion Techniques Can Contribute to Better Posttransplant Outcomes Through Reconditioning Hypoxic Cells in Lung Grafts

Presented by: K. Noda, S. Tane, A. J. Hayanga, J. D’Cunha, J. D. Luketich, N. Shigemura

 

1155 – ST266 Improves Oxygenation and Reduces Tissue Injury in an In-Situ Rat Left Lung Ischemia-Reperfusion Model

Presented by: C. F. Evans, X. Wang, X. Liu, R. Mishra, V. Mishra, S. Rahimpour, A. Zeevi, R. Banas, S. M. Pham

 

1160 – Bronchial Artery Sparing Lung Preservation: Is It Feasible?

Presented by: S. Tane, K. Noda, A. J. Hayanga, J. D’Cunha, J. D. Luketich, N. Shigemura

 

1161 – Nitrite Improves Mitochondrial Dysfunction Induced by Hypoxia/Reoxygenation in Lung Epithelial Cells: Implications for Ischemia-Reperfusion (I/R) Injury in Lung Transplantation

Presented by: A. Kumar, C. Corey, S. Shiva, M. T. Gladwin, J. D’Cunha

 

Poster Session 3: Heart Transplantation

1192 – Informative and Uninformative Variables in the Scientific Registry of Transplant Recipients

Presented by: E. M. Hsich, L. Thuita, D. McNamara, J. G. Rogers, J. Schold, E. H. Blackstone, H. Ishwaran

 

Poster Session 3: Lung Transplantation

1244 – Systematic Review and Meta-Analysis of Death After Posttransplant Lymphoproliferative Disease in Lung Transplantation

Presented by: C. A. Moore, J. Cheng, C. J. Iasella, A. R. Glanville, M. R. Morrell, R. B. Smith, J. Hayanga, J. F. McDyer, C. R. Ensor

 

1255 – Successful Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors

Presented by: C. J. Iasella, R. J. Winstead, C. A. Moore, B. A. Johnson, M. R. Morrell, J. Hayanga, A. Zeevi, E. A. Lendermon, J. F. McDyer, C. R. Ensor

 

1263 – Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Reduced Chronic Lung Allograft Dysfunction

Presented by: C. A. Moore, K. M. Harrigan, C. J. Iasella, R. Venkataramanan, M. R. Morrell, J. Hayanga, J. D’Cunha, A. Zeevi, J. McDyer, C. R. Ensor

 

Poster Session 3: Mechanical Circulatory Support

1303 – Pre-Implant Under-Expression of CCR3 and Its Ligands Predicts One-Year Mortality in Left Ventricular Assist Device Patients

Presented by: A. Nayak, C. Neill, R. L. Kormos, L. Lagazzi, I. Halder, C. McTiernan, J. Larsen, A. Inashvili, J. Teuteberg, T. N. Bachman, K. Hanley-Yanez, D. M. McNamara, M. A. Simon

 

Saturday, April 8

Sunrise Symposium: Mechanical Circulatory Support – The Interface of Design and Outcome

Co-chair: R. Kormos

 

Sunrise Symposium: Extracorporeal Photopheresis: Shedding Light on Rejection?

Co-Chair: Matthew R. Morrell

 

Plenary Session 3

0496 – Advanced Therapy Utilization and Survival in Ambulatory Patients with Advanced Heart Failure: Results from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry

Presented by: A. V. Ambardekar, M. Kittleson, M. Palardy, M. Mountis, R. Forde-McLean, A. DeVore, S. Pamboukian, J. Thibodeau, J. Teuteberg, L. Cadaret, R. Xie, L. Stevenson, G. Stewart

 

Oral Session: Not the Usual Suspects: Driving Outcomes in MCS

0500 – Temporal Patterns of Adverse Events (AE) Occurring within 60 Days of LVAD Implantation: The Concept of the AE Cascade

Presented by: J. O. Larsen, A. D. Althouse, J. J. Teuteberg, C. M. Sciortino, C. V. Nikas, L. F. Lagazzi, M. S. Sharbaugh, S. U. Iturra, N. M. Kunz, E. M. Dunn, K. L. Lockard, R. L. Kormos

 

Oral Session: Seeing the Patient Beyond the Device

0504 – Glad to Have a VAD Across Intermacs Profiles

Presented by: F. Pagani, M. Kittleson, G. Stewart, A. DeVore, M. Brinkley, S. Myers, M. Miller, D. Naftel, J. J. Teuteberg, L. W. Stevenson

 

Oral Session: Getting to the Heart of the Matter: Psychosocial Predict Outcomes in Transplant and MCS

0243 – Social and Clinical Characteristics Associated with Increased Short Term Mortality in Non-Inotrope Dependent Patients Undergoing Left Ventricular Assist Device Therapy: Results from InterMACS

S. M. Joseph, R. L. Kormos, J. Teuteberg, A. Althouse, J. Cowger.

 

Oral Session: The Weighting Game: Impact of Obesity, Age, and Other Comorbidities in MCS

0471 – Adverse Events After Device Implantation Are More Common in Obese Patients: An IMACS Registry Analysis

Presented by: S. J. Forest, R. Xie, J. K. Kirklin, J. A. Cowger, Y. Xia, A. I. Dipchand, C. Sivathasan, C. Merry, L. H. Lund, R. Kormos, T. Nakatani, U. Jorde, D. J. Goldstein

 

Oral Session: Optimizing Early Outcomes after Lung Transplantation

0482 – Treatment of Antibody Mediated Rejection of the Lung Allograft with Carfilzomib-Based Therapy

Presented by: C. R. Ensor, A. Zeevi, S. A. Yousem, M. Mangiola, M. Marrari, M. R. Morrell, J. M. Pilewski, J. D’Cunha, J. F. McDyer

 

Oral Session: Influencing Long-term Outcomes in Lung Transplantation

0516 – Regulation of KLRG1 Gene Expression by T-bet Correlates with Human Cytomegalovirus-Specific CD8+ T Cells Effector Function

Presented by: A. Hoji, I. Popescu, M. Pipeling, H. Mannem, J. McDyer

Magee’s Pregnancy Recovery Center Expands to Aid Expectant Mothers Struggling with Opioid Dependency

In 2014, the Pregnancy Recovery Center (PRC) at Magee-Womens Hospital of UPMC became one of the country’s first programs to provide concurrent treatment for opioid dependency as well as prenatal care and delivery. Through the support of a Centers of Excellence (COE) grant from the Pennsylvania Department of Human Services, the PRC has expanded to five new locations in three counties, providing comprehensive services for expectant mothers closer to home. Patients can now be seen in Butler, Clairton, Beaver, Natrona Heights and Monroeville, and all deliveries take place at Magee.

“The benefit of being able to remain close to home while managing their pregnancy and treatment cannot be underestimated for these women. With this COE grant, we are now able to bring the expertise of our PRC specialists to patients in outlying areas where these services are needed the most to continue to reduce the impact that opioid addiction has on mothers and babies throughout western Pennsylvania,” said Patty Genday, executive director of women’s services, Magee-Womens Hospital of UPMC.

All PRC patients are prescribed buprenorphine—which is effective for converting patients off opioids—or another opioid replacement, on an outpatient basis. Treatment also includes behavioral counseling, clinic visits and consultations with social workers, in addition to routine prenatal check-ups. Counseling services at the new PRC locations are conducted in conjunction with regional behavioral health providers.

“Treatment for addiction is most effective when integrated with treatment for physical and mental health as well as social services. Most people with substance use disorders, particularly opioid use disorder, also have a daunting array of other health and psychological problems,” said Antoine Douaihy, MD, senior academic director of addiction medicine services at Western Psychiatric Institute and Clinic of UPMC. “This comprehensive program provides treatment of substance use disorder and any related psychiatric disorders that are highly prevalent in pregnant women. Treating one improves outcomes in treating the other.”

Research suggests that pregnant women using buprenorphine instead of methadone recover faster after birth, and babies experience fewer side effects. Sixty percent of babies born at Magee to mothers treated with methadone require medication for withdrawals, whereas only 35 percent of newborns whose mothers received treatment from the PRC require medication.

“For many women, pregnancy enhances their chances of overcoming their opioid dependency,” said Michael England, MD, director of the PRC. “We are offering women and their babies an opportunity to move forward.”

McGowan Institute for Regenerative Medicine Faculty Member Publication Named a NIEHS Top Paper of 2016

The National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS), recently honored its 2016 Papers of the Year—the top 25 of 2700 publications.

In that elite group, McGowan Institute for Regenerative Medicine faculty member Fabrisia Ambrosio, PhD, MPT, Director of Rehabilitation for UPMC International and an Associate Professor in the Department of Physical Medicine & Rehabilitation at the University of Pittsburgh, and her team were recognized for their paper entitled “Arsenic promotes NF-kB-mediated fibroblast dysfunction and matrix remodeling to impair muscle stem cell function,” published in the journal Stem Cells.

McGowan Institute faculty member Donna Stolz, PhD, Associate Director of the Center for Biologic Imaging, University of Pittsburgh School of Medicine, and an Associate Professor in the Departments of Cell Biology and Pathology at the University of Pittsburgh, is a co-author on the study.

The paper’s abstract reads:

Arsenic is a global health hazard that impacts over 140 million individuals worldwide. Epidemiological studies reveal prominent muscle dysfunction and mobility declines following arsenic exposure; yet, mechanisms underlying such declines are unknown. The objective of this study was to test the novel hypothesis that arsenic drives a maladaptive fibroblast phenotype to promote pathogenic myomatrix remodeling and compromise the muscle stem (satellite) cell (MuSC) niche. Mice were exposed to environmentally relevant levels of arsenic in drinking water before receiving a local muscle injury. Arsenic-exposed muscles displayed pathogenic matrix remodeling, defective myofiber regeneration and impaired functional recovery, relative to controls. When naïve human MuSCs were seeded onto three-dimensional decellularized muscle constructs derived from arsenic-exposed muscles, cells displayed an increased fibrogenic conversion and decreased myogenicity, compared with cells seeded onto control constructs. Consistent with myomatrix alterations, fibroblasts isolated from arsenic-exposed muscle displayed sustained expression of matrix remodeling genes, the majority of which were mediated by NF-κB. Inhibition of NF-κB during arsenic exposure preserved normal myofiber structure and functional recovery after injury, suggesting that NF-κB signaling serves as an important mechanism of action for the deleterious effects of arsenic on tissue healing. Taken together, the results from this study implicate myomatrix biophysical and/or biochemical characteristics as culprits in arsenic-induced MuSC dysfunction and impaired muscle regeneration. It is anticipated that these findings may aid in the development of strategies to prevent or revert the effects of arsenic on tissue healing and, more broadly, provide insight into the influence of the native myomatrix on stem cell behavior.

Women Less Likely to be Academic Grand Rounds Speakers than Men

Women are less likely than men to be chosen as speakers during grand rounds, the academic mainstay of expert-delivered lectures used to share patient-care guidelines and cutting-edge research within clinical departments. Those findings by researchers at the University of Pittsburgh School of Medicine were published today in JAMA Internal Medicine.

Despite women comprising 47 percent of medical students, 46 percent of residents and 36 percent of faculty nationwide, only 26 percent of grand rounds speakers were women. Across clinical specialties, grand rounds speakers were 44 percent less likely than medical students, 39 percent less likely than residents, and 21 percent less likely than faculty to be women. Additionally, speakers invited from outside institutions were less likely to be women than those invited to speak at grand rounds from among an institution’s own personnel.

“The people at the podiums do not resemble the people in the audience,” said Julie Boiko, MD, MS, who led the study while a medical student at the Pitt School of Medicine. “While gender representation and equality in medicine has been an important area of student discussion in recent years, this is the first time we have data to support that there may be a gender bias in speaker selection at academic grand rounds.”

Data for the JAMA research letter was collected from nine major clinical specialties and 79 medical schools and academic hospitals. In total, researchers analyzed more than 200 grand rounds websites and calendar listings for speaker series, as well as more than 7,000 individual sessions for speaker gender and institutional affiliations.

As follow up to this study, researchers plan to identify specific factors associated with having greater gender balance on grand rounds speaker rosters.

“We were surprised by the consistency of this underrepresentation across most specialties and the discovery that speakers invited from outside a given institution are less likely to be women than speakers invited from within the institution,” said Alyce Anderson, coauthor of the study and an MD/PhD. candidate at the Pitt School of Medicine. “With this data, speaker planning committees, departments and institutions can strive for gender representation that approximates that of individual clinical specialties’ faculty and/or trainees. Such efforts may have a positive effect on retaining women in the academic medical workforce.”

Boiko currently is a resident physician in the Department of Pediatrics at the University of California, San Francisco. Additional coauthor Rachael Gordon is an MD/PhD student at the Pitt School of Medicine.

Thomas E. Starzl, MD, PhD, ‘Father of Transplantation,’ Dies at 90

Dr. Thomas E. Starzl, known as the “father of transplantation” for his role in pioneering and advancing organ transplantation from a risky, rare procedure to an accessible surgery for the neediest patients, died peacefully Saturday, March 4, 2017, at his home in Pittsburgh.
Dr. Starzl is survived by his wife of 36 years, Joy Starzl, of Pittsburgh, son Timothy (Bimla) of Boulder, Colorado, and a grandchild Ravi Starzl (Natalie) of Pittsburgh. He was preceded in death by a daughter, Rebecca Starzl, and a son, Thomas F. Starzl.

His family issued the following statement:

“Thomas Starzl was many things to many people. He was a pioneer, a legend, a great human, and a great humanitarian. He was a force of nature that swept all those around him into his orbit, challenging those that surrounded him to strive to match his superhuman feats of focus, will and compassion. His work in neuroscience, metabolism, transplantation and immunology has brought life and hope to countless patients, and his teaching in these areas has spread that capacity for good to countless practitioners and researchers everywhere. With determination and irresistible resolve, Thomas Starzl advanced medicine through his intuition and uncanny insight into both the technical and human aspects of even the most challenging problems. Even more extraordinary was his ability to gift that capacity to those around him, allowing his students and colleagues to discover the right stuff within themselves. Nobody who spent time with Thomas Starzl could remain unaffected.

Thomas Starzl is a globally recognized pioneer in science and medicine, but beyond that mantle, he was simply known and loved for the person that he was. He was husband and soulmate to Joy Starzl, father to Tim Starzl (Bimla), Thomas F. Starzl and Rebecca Starzl, grandfather to Ravi Starzl (Natalie), and godparent to Lamont Chatman and Angela Ford. He was deeply loved for his tremendous wit, humor and sensitivity. His traits of humility, keen observation and seemingly limitless memory fused to create a unique personality that was at the same time inspiring and comforting. His drive to always remain in motion led him on grand adventures around the world, from his beloved Colorado Rockies to the Sea of Japan, from the tundra of northern Finland to the beaches of Monaco. He had an expansive knowledge and appreciation for all music, from classical to modern jazz. He enjoyed watching and analyzing movies, often researching their production and topic matter for hours, both before and after repeated viewings. He raised and cared for many canine companions, including Bevo, Thor, Maggie, Tiki, Shelby, Basta, Chooloo and Ophelia. Their unconditional love was matched only by his own love for them. He will be greatly missed.”

Dr. Starzl joined the University of Pittsburgh School of Medicine in 1981 as professor of surgery, and led the team of surgeons who performed Pittsburgh’s first liver transplant. Thirty liver transplants were performed that year, launching the liver transplant program—the only one in the nation at the time.

Until he retired from clinical and surgical service in 1991, Dr. Starzl served as chief of transplantation services at Presbyterian University Hospital (now UPMC Presbyterian), Children’s Hospital of Pittsburgh (now Children’s Hospital of Pittsburgh of UPMC) and the Veterans Administration Hospital in Pittsburgh, overseeing the largest and busiest transplant program in the world. He then assumed the title of director of the University of Pittsburgh Transplantation Institute, which was renamed the Thomas E. Starzl Transplantation Institute in 1996. Since 1996, Dr. Starzl held the titles of Distinguished Service Professor of Surgery at the University of Pittsburgh and director emeritus of UPMC’s Thomas E. Starzl Transplantation Institute.

Dr. Starzl performed the world’s first liver transplant in 1963 and the first successful liver transplant in 1967, both while at the University of Colorado. Despite prevailing worldwide pessimism regarding the ability to transplant allogenic (non-identical) human kidneys, he successfully combined azathioprine and corticosteroids in allogenic kidney transplants performed in 1962 and 1963, leading to the largest series of kidney transplants and invigorating clinical attempts throughout the world.

In addition to developing azathioprine and corticosteroid immunosuppression, Dr. Starzl later introduced anti-lymphocyte globulin and cyclosporine to prevent organ rejection. It was this development in 1980 that advanced transplantation from an experimental procedure to an accepted form of treatment for patients with end-stage liver, kidney and heart disease. It also allowed surgeons to explore the feasibility of transplanting other organs, such as the pancreas and lung.

In 1989, Dr. Starzl announced the first-time use of FK506 (tacrolimus) as a more effective anti-rejection agent. FK506 greatly improved patient and graft survival rates for liver and other organ transplants and made intestinal transplantation possible for the first time. Five years later, FK506 was approved for clinical use by the U.S. Food and Drug Administration.

Under Dr. Starzl’s leadership, the Thomas E. Starzl Transplantation Institute also researched the feasibility of cross-species, or xenotransplantation, for addressing the chronic shortage of human organs. In 1992 and 1993, his team made history when surgeons performed two baboon-to-human liver transplants. Dr. Starzl himself performed six baboon-to-human kidney transplants in 1963 and 1964 and the world’s first chimpanzee liver xenotransplants in three children between 1969 and 1974.

A major focus of Dr. Starzl’s later research was transplant tolerance and chimerism—the existence of cells from both the donor and recipient. His work in this area offered significant contributions to the understanding of transplant immunology, particularly with respect to how and why organs are accepted.

Dr. Starzl was the recipient of more than 200 awards and honors, including the Lasker-DeBakey Clinical Medical Research Award from the Albert and Mary Lasker Foundation in 2012; the 2004 Presidential National Medal of Science, the nation’s highest scientific honor; the David M. Hume Memorial Award from the National Kidney Foundation; the Brookdale Award in Medicine presented by the American Medical Association Board of Trustees and the Brookdale Foundation; the Sheen Prize from the American College of Surgeons; the Bigelow Medal from the Boston Surgical Society; the Medallion for Scientific Achievement presented by the American Surgical Association; the William Beaumont Prize from the American Gastroenterological Association; the Peter Medawar Prize of The Transplant Society; the Jacobson Innovation Award of the American College of Surgeons; the International Chiron Award from the Italian Academy of Science; the Lannelongue International Medal from the Academie Nationale De Chirurgie (National Academy of Surgery, France); the King Faisal International Prize for Medicine from Riyadh, Kingdom of Saudi Arabia; the Rhoads Medal of the American Philosophical Society; the Prince Mahidol Award from Mahidol University at Salaya, Bangkok, Thailand; the Gustav O. Lienhard Award from the Institute of Medicine; and 26 honorary doctorates from universities around the world.

Dr. Starzl’s national and international endeavors included membership in more than 60 professional and scientific organizations. He served as president of the Transplantation Society, founding president of the American Society of Transplant Surgeons and founding president of the Transplant Recipients International Organization. In 1992, he was inducted as one of only five American members into the prestigious National French Academy of Medicine. A sought-after speaker, Dr. Starzl gave more than 1,300 presentations at major meetings throughout the world. He belonged to the editorial boards of 40 professional publications and authored or co-authored more than 2,200 scientific articles, four books and 300 book chapters.

According to the Institute for Scientific Information (ISI), Dr. Starzl for a time averaged one paper every 7.3 days, making him one of the most prolific scientists in the world. In 1999, ISI identified him as the most cited scientist in the field of clinical medicine, a measure of his work’s lasting influence and utility. The book, “1,000 Years, 1,000 People: Ranking the Men and Women Who Shaped the Millennium,” ranked Dr. Starzl 213th on its list of the 1,000 people having the greatest influence on the world in the preceding 1,000 years.

Dr. Starzl’s autobiography, “The Puzzle People: Memoirs of a Transplant Surgeon,” was published by the University of Pittsburgh Press in 1992. Translations have been published in Italian, Japanese, Korean and Spanish. All author’s royalties are donated to the Transplant Recipients International Organization.

Dr. Starzl was born March 11, 1926 in LeMars, Iowa, the son of newspaper editor and science fiction writer Rome Starzl and loving mother Anna Laura Fitzgerald.

He attended Westminster College in Fulton, Mo., where he earned his bachelor’s degree in biology. He went on to the Northwestern University Medical School in Chicago, where in 1950 he received a master’s degree in anatomy and in 1952 earned both a doctoral degree in neurophysiology and a medical degree with distinction.

Following postgraduate work at Johns Hopkins Hospital in Baltimore, Dr. Starzl pursued his interest in surgery and research with a fellowship and residencies at Johns Hopkins, the University of Miami and the Veterans Administration Research Hospital in Chicago. He was a Markle Scholar in Medical Science, a distinguished honor bestowed annually to a small group of exceptionally promising young physicians in academic medicine. Dr. Starzl served on the faculty of Northwestern University from 1958 to 1961 and joined the University of Colorado School of Medicine as an associate professor in surgery in 1962. He was promoted to professor in 1964 and served as chairman of the department of surgery from 1972 to 1980.

Regarding Dr. Starzl:
“Tom Starzl was a man of unsurpassed intellect, passion and courage whose work opened up a new frontier in science and forever changed modern medicine. He will be remembered for many things, but perhaps most importantly for the countless lives he saved through his pioneering work. We at Pitt have lost a friend and colleague who took the University to new heights of recognition and achievement — Patrick Gallagher, Chancellor, University of Pittsburgh

“Dr. Starzl’s pioneering work in organ transplantation set the standard for innovation and excellence at UPMC. An extraordinarily skilled and compassionate surgeon and brilliant researcher, he brought hope to the sickest of the sick, a legacy that we continue to build on today.” — Jeffrey A. Romoff, President and CEO, UPMC

“Tom Starzl’s tremendous respect and affection for his patients became the life force of his career. Countless lives were saved through his advances in technique and his pioneering work to prevent organ rejection. There is not a transplant surgeon worldwide who has not, in some way, been influenced by his work.” — Arthur S. Levine, MD, University of Pittsburgh Senior Vice Chancellor for the Health Sciences and John and Gertrude Petersen Dean of the University of Pittsburgh School of Medicine

“Tom Starzl devoted his life to the cause of human health and advanced the field of medicine in ways that were unimaginable to most. He applied a combination of extraordinary talent and steely determination to build an unparalleled record of impact as a uniquely gifted surgeon, a visionary researcher, a prolific scholar and the single most influential teacher in the ground-breaking field of organ transplantation. In the process, he became a hero to countless transplant patients, their families and their physicians, while also playing a key role in the elevation of Pitt and in the transformation of Pittsburgh.” — Mark A. Nordenberg, Chancellor Emeritus, University of Pittsburgh

“Words cannot convey how deeply saddened we all are with the passing of Dr. Starzl. It’s impossible to quantify the magnitude of his contributions to the field of transplant. I feel so deeply honored and privileged to have had the opportunity to know him personally over the last few years. The world has lost today the greatest figure in the history of transplant, and I have lost my greatest mentor. The Starzl Transplant Institute will continue to work tirelessly to carry on his rich legacy.” — Dr. Abhinav Humar clinical director of the Thomas E. Starzl Transplantation Institute and chief of the Division of Transplantation in the Division of Surgery at UPMC

Physicians and Researchers Present at the American College of Cardiology (ACC) 66th Annual Scientific Session

The UPMC Heart and Vascular Institute will be well-represented at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, DC. Faculty research will be featured in both oral and poster presentations throughout the conference, including:

 

Friday, March 17

Session 1120: Novel Echocardiographic Methods for Assessing Cardiac Function

Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain

Presented by: Masataka Sugahara, Dennis McNamara, Joan Briller, Leslie Cooper, Julie Damp, Mark H. Drazner, James Fett, Eileen Hsich, Navin Rajagopalan, John Gorcsan

 

Session 1130: Innovations in Practice Management and Social Media

Formal CPR Status Policy and Process Increased Documentation Rates

Presented by: Joshua E. Levenson, Aken Desai, Karen Kelly, Emilie Prout, Joon Lee, Mark Schmidhofer, Winifred Teuteberg

 

Session 1149: Arrhythmias and Clinical EP: Devices 2

Persistent Gender Disparities in Implantable Cardioverter-Defibrillator Therapy

Presented by: Amber E. Johnson, Shubash Adhikari, Andrew Althouse, Floyd Thoma, Oscar Marroquin, Stephen Koscomb, Leslie Hausmann, Larissa Myaskovsky, Samir Saba

 

Session 1150: Arrhythmias and Clinical EP: AF Ablation

Characterization of Pulmonary Vein Reconnection Post Cryoballoon Ablation

Presented by: Shivang Shah, Wenjie Xu, Evan Adelstein, Andrew Voigt, Samir Saba, Sandeep Jain

 

Session 1157: Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease

Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study

Presented by: Birgit Vogel, Usman Baber, Samantha Sartori, Jaya Chandrasekhar, Serdar Farhan, Michela Faggioni, Sabato Sorrentino, Annapoorna Kini, William Weintraub, Sunil Rao, Samir Kapadia, Sandra Weiss, Craig Strauss, Catalin Toma, J. Muhlestein, Anthony C. DeFranco, Mark Effron, Stuart Keller, Brian Baker, Stuart Pocock, Timothy Henry, Roxana Mehran

 

Session 4101: Advanced heart Failure and VAD Therapy
Presented by: Jeffrey Teuteberg

 

Saturday, March 18

Session 904: Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review

Simplified Measures of Right Ventricular and Atrial Remodeling Are Predictive of Outcomes in Patients With Pulmonary Hypertension

Presented by: Masataka Sugahara, Keiko Ryo-Koriyama, Akiko Goda, Omar Batal, Marc Simon, John Gorcsan

 

Session 1196: Nuclear Cardiology: Beyond Perfusion

Regional Right Ventricular (RV) Function as Determined by Gated Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD) Implantation

Presented by: Christopher B. Link, Aditi Nayak, Robert Kormos, Marc Simon, Jeffrey Teuteberg, Luigi Lagazzi, Andrew Althouse, Prem Soman

 

Session 1201: Advances in HCM, PPCM and Other Cardiomyopathies

Extended Course of Recovery in Patients With Peripartum Cardiomyopathy Assessed by Left Ventricular Wall Distensibility

Presented by: Masataka Sugahara, Dennis McNamara, Lori Blauwet, Rami Alharethi, Paul Mather, Kalgi Modi, Richard Sheppard, Vinay Thohan, Gretchen Wells, John Gorcsan

 

Session 669: Distinct Phenotypes in HFpEF: Beyond Ejection Fraction

669-03 – Diagnostic Evaluation of Patients with Dyspnea and Normal LVEF
Presented by: John Gorcsan

 

Session 1226: Put Your Codon! Genetic Insights Into Heart Failure

G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study

Presented by: Amber E. Johnson, Karen Hanley-Yanez, Clyde Yancy, Anne Taylor, Arthur Feldman, Dennis McNamara

 

Session 1242: Timely Topics in Acute Coronary Syndromes

Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes

Michela Faggioni, Usman Baber, Jaya Chandrasekhar, Birgit Vogel, Samantha Sartori, Melissa Aquino, Annapoorna Kini, William Weintraub, Samir Kapadia, Sandra Weiss, Craig Strauss, Clayton Snyder, Catalin Toma, J. Muhlestein, Anthony C. DeFranco, Mark B. Effron, Stuart Keller, Brian Baker, Stuart Pocock, Timothy Henry, Sunil Rao, Roxana Mehran

 

Session 1257: FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension

1257-408 / 408 – When the Liver Gets Sacked by the Heart Sac: A Diagnostic Challenge of Mixed Heart and Liver Pathology
Presented by: Ahmad Masri, John Gorcsan

 

Session 1245: New Technologies in Echocardiography

1245-219 / 219 – Assessment of Right Ventricular Energy Loss and Efficiency Using Novel Vector Flow Mapping

Presented by: Masataka Sugahara, Nina Hasselberg, Marc Simon, John Gorcsan

 

Session 1246: Nuclear Cardiology: Quality

Repeatability of Appropriateness Category Allocation by Trained Physicians

Presented by: Daniel Nguyen, Aditi Nayak, Christopher Pray, Christopher Link, Andrew Althouse, Prem Soman

 

Session 702: The Forgotten Chamber: The Right Ventricle in Heart Failure

RV Failure After LVAD: Predictable and Preventable?
Presented by: Jeffrey Teuteberg

 

Session 1235: Innovations in Cardiovascular Risk Assessment and Reduction

Ideal Cardiovascular Health Metrics in Couples: A Community-Based Population Study

Presented by: Oluremi Ajala, Sebhat Erqou, Claudia Bambs, Michael Sharbaugh, Andrew Althouse, Aryan Aiyer, Kevin Kip, Steven Reis

 

Session 1230: Predicting the Future: Observations and Discoveries From Registries and Databases

Pulmonary Vascular Resistance Predicts Mortality in End-Stage Renal Disease Patients With Pulmonary Hypertension

Presented by: Jonathan Wolfe, Gavin Hickey, Andrew Althouse, Michael Sharbaugh, Deepak Kumar Pasupula, Dustin Kliner, Michael Mathier, Prem Soman

 

Session 727: Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response

Expanding the Diagnostic Toolbox for Aortic Stenosis
Presented by: João Cavalcante

 

Session 716: Pregnancy and Heart Disease

Peripartum Cardiomyopathy – Long term Outcomes and Management Options
Presented by: Dennis McNamara

 

Session 4103: Advanced Heart Failure and VAD Therapy
Presented by: Jeffrey Teuteberg

 

Sunday, March 19

Session 732: Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology

Nuclear Cardiology: Risk Stratification
Presented by: Prem Soman

 

Session 738: Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology

What to do if the left ventricle fails after mitral valve surgery
Presented by: Robert Kormos

 

Session 770: Great Debates in Cardiac MRI

Debate Con: Stress MRI is the Test of Choice for Ischemia Assessment
Presented by: Prem Soman

 

Session 4105: Advanced Heart Failure and VAD Therapy
Presented by: Jeffrey Teuteberg

 

Session 1274: The Challenges of Outcome Prediction in Valvular Heart Disease

Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era

Presented by: Islam Abdelkarim, Jeffrey Xu, Michael Sharbaugh, Andrew Althouse, William Katz, Frederick Crock, Matthew Harinstein, Dustin Kliner, Forozan Navid, Joon Lee, John Schindler, Thomas Gleason, João Cavalcante

 

Session 1282: Advances in Chronic Total Occlusion Intervention

The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry

Presented by: Judit Karacsonyi, Khaldoon Alaswad, Farouc Jaffer, Robert Yeh, Dimitrios Karmpaliotis, Jeffrey Moses, Ajay Kirtane, Manish Parikh, Ziad Ali, David Kandzari, Nicholas Lembo, William Lombardi, R. Michael Wyman, Anthony Doing, Catalin Toma, James Choi, Mitul Patel, Ehtisham Mahmud, Barry Uretsky, Aris Karatasakis, Bavana Rangan, Imre Ungi, Craig Thompson, Subhash Banerjee, Emmanouil Brilakis

 

Session 1307M: Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology

Predictors of a Positive Technetium Pyrophosphate Scan in Patients With Suspected Cardiac Amyloidosis

Presented by: Ahmad Masri, Ricardo Nieves, Michael S. Sharbaugh, Andrew Althouse, William Follansbee, João Cavalcante, Prem Soman

 

Session 1221M: TAVR outcomes Prognostication

Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit

Presented by: João Cavalcante, Islam Abdelkarim, Michael Sharbaugh, Andrew Althouse, Jeffrey Xu, Wei Han, William Katz, Frederick Crock, Matthew Harinstein, Dustin Kliner, Forozan Navid, Joon Lee, John Schindler, Thomas Gleason

 

Session 769: Life After LVAD: The Good, The Bad and The Ugly

Right Ventricular Failure After LVAD
Presented by: Robert Kormos

 

Session 785: Radiation from Diagnostic Imaging: Risk-benefit Analysis
Panelist: Prem Soman

UPMC Updates in Otolaryngology: A Monthly Webinar Series

ent-webinar-series_880x135

 

 

The UPMC Department of Otolaryngology presents a free webinar series — UPMC Updates in Otolaryngology.

Upcoming webinars include:

December 6, 2016 – 8 p.m.: Tinnitus Retraining Therapy: How to Live with the Sounds
Presented by: Lori Zitelli, AuD, CCA-A
Moderated by: David Eibling, MD — Professor, Department of Otolaryngology

January 10, 2017 – 8 p.m.: Evaluation of Noisy Breathing in Infants and Children
Presented by: Jeffrey Simons, MD — Associate Professor, Department of Pediatric Otolaryngology
Moderated by: Jonas Johnson, MD, FACS — Professor and Chairman, Department of Otolaryngology

February 7, 2017 – 8 p.m.: Update in Implantable Hearing Devices
Presented by: Barry Hirsch, MD — Professor, Department of Otolaryngology
Moderated by: Jonas Johnson, MD, FACS — Professor and Chairman, Department of Otolaryngology

March 7, 2017 – 8 p.m.: Neurostimulation Therapy for Obstructive Sleep Apnea
Presented by: Ryan Soose, MD — Assistant Professor, Department of Otolaryngology
Moderated by: Bridget Hathaway, MD — Assistant Professor, Department of Otolaryngology

April 4, 2017 – 8 p.m.: Update on Sino-Nasal Malignancy
Presented by: Eric Wang, MD — Associate Professor, Department of Otolaryngology
Moderated by: David Eibling, MD — Professor, Department of Otolaryngology

May 9, 2017 – 8 p.m.: Advances and Novel Therapeutics in the Treatment of Chronic Rhinosinusitis
Presented by: Stella Lee, MD — Associate Professor, Department of Otolaryngology
Moderated by: TBD

June 6, 2017 –8 p.m.: Advances in Management of Oropharynx Cancer: HPV, Robotic Surgery, and Immunotherapy
Presented by: Robert Ferris, MD, PhD — Associate Professor, Department of Otolaryngology
Moderated by: Barry Schaitkin, MD, FACS — Professor, Department of Otolaryngology

For more information, to register for a webinar, or to view all past webinars, visit the Chorus Call website.

 

Page 1 of 72:1 2 3 4 »Last »